SCHEMBL851111

SCHEMBL851111

C=C(C)C(=O)NC(CC)[Si](O[Si](C)(C)c1ccccc1)(O[Si](C)(C)c1ccccc1)O[Si](C)(C)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TGFBR1 P36897 1/20 0.34
MAPT P10636 1/20 0.32
KLK7 P49862 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
LMNA P02545 2/20 0.32
HPGD P15428 2/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
POLB P06746 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
GAA P10253 1/20 0.31
RECQL P46063 1/20 0.31
BLM P54132 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
GPR174 Q9BXC1 1/20 0.31
MTNR1A P48039 2/20 0.31
MTNR1B P49286 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10756452 0.82 ALDH1A1 (0.35) KDM4EALDH1A1TGFBR1MAPTNPSR1
SCHEMBL1517421 0.82 CYP2C19 (0.38) ALDH1A1MAPTLMNATSHRPOLB
SCHEMBL308679 0.79 TGFBR1 (0.39) TGFBR1
SCHEMBL514780 0.78 TGFBR1 (0.38) TGFBR1
SCHEMBL1517401 0.76 TGFBR1 (0.37) TGFBR1
SCHEMBL393902 0.74 ELANE (0.33) ALDH1A1MAPTHPGD
SCHEMBL10751506 0.74 TGFBR1 (0.35) TGFBR1
SCHEMBL850357 0.74 TGFBR1 (0.35) TGFBR1
SCHEMBL10753636 0.74 TGFBR1 (0.35) TGFBR1
SCHEMBL10751465 0.74 TGFBR1 (0.37) TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432808-B1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2015-10-21 EP claimed
US-9097839-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2015-08-04 US claimed
US-8383744-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2013-02-26 US claimed
US-20120172478-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2012-07-05 US claimed
US-8163206-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2012-04-24 US claimed
EP-2432808-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS Novartis AG (CH) 2012-03-28 EP claimed
WO-2010133680-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2010-11-25 WO claimed
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS ALCON INC. (CH) 2010-11-25 US claimed
US-20100258961-A1 Method for making silicone hydrogel contact lenses ALCON INC. (CH) 2010-10-14 US claimed
EP-3486711-A1 LENS-FORMING MATERIALS COMPRISING PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES Novartis AG (CH) 2019-05-22 EP disclosed
US-9097839-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2015-08-04 US disclosed
US-9066981-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2015-06-30 US disclosed
US-20140100291-A1 Actinically-Crosslinkable Siloxane-Containing Copolymers NOVARTIS AG (CH) 2014-04-10 US disclosed
US-8642712-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2014-02-04 US disclosed
EP-0675910-B1 NOVEL MACROMONOMERS BAUSCH & LOMB (US) 1997-09-17 EP disclosed
US-5563184-A CONTACT LENSES BAUSCH & LOMB INCORPORATED (US) 1996-10-08 US disclosed
EP-0675910-A1 NOVEL MACROMONOMERS. BAUSCH & LOMB (US) 1995-10-11 EP disclosed
US-5387663-A Polymerized with hydrophilic or hydrophobic monomers for biomedical devices, contact lenses BAUSCH & LOMB INCORPORATED (US) 1995-02-07 US disclosed
WO-1994015980-A1 NOVEL MACROMONOMERS BAUSCH & LOMB INCORPORATED (US) 1994-07-21 WO disclosed
US-4711943-A IMPROVED OXYGEN PERMEABILITY AND STABILITY SOLA U.S.A. INC. (US) 1987-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS VCL, MACF1, CFL1 KDM4E 2968/4885ALDH1A1 2874/4885TGFBR1 865/4885
US-20140100291-A1 Actinically-Crosslinkable Siloxane-Containing Copolymers ATRIP, ATR, MACF1 KDM4E 2683/4885ALDH1A1 1684/4885TGFBR1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.